Description
Gozerelin-Alvogen Implant 3.6 mg Syringe №1
Ingredients:
Gozerelin-Alvogen contains 3.6 mg of the active ingredient goserelin acetate, which is a synthetic hormone that acts as a gonadotropin-releasing hormone (GnRH) agonist.
Mechanism of Action:
Gozerelin-Alvogen exerts its pharmacological effects by acting as a GnRH agonist. It initially stimulates the release of certain hormones, followed by a sustained suppression of hormone production. This mechanism helps in managing conditions like prostate cancer and endometriosis.
Pharmacological Properties:
The active ingredient in Gozerelin-Alvogen, goserelin acetate, acts on the pituitary gland to inhibit the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing the production of testosterone and estrogen in the body.
Indications for Use:
Gozerelin-Alvogen is indicated for the treatment of advanced prostate cancer, endometriosis, and certain gynecological disorders. It works by suppressing the production of certain hormones in the body.
Contraindications:
Gozerelin-Alvogen is contraindicated in individuals with a known hypersensitivity to goserelin acetate or any of the other ingredients in the product. It should not be used during pregnancy.
Side Effects:
Common side effects of Gozerelin-Alvogen may include hot flashes, decreased libido, erectile dysfunction, and injection site reactions. It is important to consult a healthcare provider if any adverse reactions occur.
Usage Instructions:
Gozerelin-Alvogen should be administered as a subcutaneous implant with a dosage of 3.6 mg once every 28 days under the supervision of a healthcare provider. The implant is typically placed in the abdominal area.
Benefits Compared to Analogues:
Comparative studies have shown that Gozerelin-Alvogen has similar efficacy to other GnRH agonists in the treatment of prostate cancer, with a favorable side effect profile. Its convenient dosing schedule and long-acting formulation make it a preferred choice for many patients.
Suitable Patient Groups:
Gozerelin-Alvogen is suitable for adult patients with advanced prostate cancer, endometriosis, or certain gynecological disorders. It is not recommended for use in children, pregnant women, or individuals with known hypersensitivity to goserelin acetate.
Storage and Shelf Life:
Gozerelin-Alvogen should be stored at room temperature (20-25°C) in the original packaging to protect from light and moisture. The shelf life of the product is as indicated on the packaging.
Packaging Description:
The product Gozerelin-Alvogen is supplied as a subcutaneous implant in a sterile syringe. Each package contains one 3.6 mg implant for single use.
Scientific Evidence:
Studies have shown that Gozerelin-Alvogen is effective in the treatment of prostate cancer by reducing testosterone levels, which can slow the growth of cancer cells. Research also supports its use in managing endometriosis symptoms by suppressing estrogen production.
Additional Information:
It is important to discuss any existing medical conditions or medications with your healthcare provider before starting treatment with Gozerelin-Alvogen. Regular monitoring and follow-up visits may be necessary to assess the response to treatment.
